

BG SALES-TRADING MORNING DU 08/02/2016

LA SEANCE DE LA VEILLE

INDICES U.S & JAPON				SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS			
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD	
DJ	16205	-1,3%	-0,3%	Telecom Op.	0,8	7,7	Auto & Part	1,1	-20	
NASDAQ	4363,1	-3,2%	-0,8%	Household Products	0,7	1,6	Basic Resources	0	-7	
S&P 500	1880	-1,8%	-0,4%	Utilities	0,3	7,5	Banks	-0,1	-19,9	
NIKKEI	17004,3	1,1%	-	Food Bev & Tobacco	-0,1	-2,1	Industrial Goods & Serv.	-0,1	-8,9	
				SECTEURS S&P : WORST PERFS.			SECTEURS STOXX : WORST PERFS			
				S&P	Var %	YTD	STOXX	Var %	YTD	
				Consumer Serv.	-4,5	-8,3	Media	-2,6	-9	
				Consumer Durables	-4	-7,2	Technology	-2,1	-10,5	
				Spec. Retail	-4	-14,8	Insurance	-2	-16,5	
				IT, SOFTW & Serv.	-3,7	-8,8	Real Estate	-1,7	-8,4	

Valeurs les plus traitées hier vs. Moy. 3M

CAC 40			EURO STOXX 50			STOXX 600		
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%
ARCELORMITTAL	3,5	-5,5	INTESA SANPAOLO	2,4	-3,9	MICRO FOCUS INTL	1349	0,7
BNP PARIBAS	41,6	1,5	BNP PARIBAS	41,6	1,5	EMS-CHEMIE HOLDING	453	5,8
KERING	154,9	1,6	DEUTSCHE TELEKOM	14,9	-3,8	NOKIAN RENKAAT OYJ	33,9	11,2
ORANGE	15,2	-3	BANCO SANTANDER	3,7	2,5	ANGLO AMERICAN PLC	363,4	10,7
LEGRAND SA	49,3	-0,7	ORANGE	15,2	-3	GENMAB A/S	750	-6,4

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S				DEVICES				MAT. PREMIERES			
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	100	0%	0,7%	€/§	1,1143	-0,1%	2,5%	BRENT	33,9	0,6%	-5,2%
U.S 10 ANS	103,5	-0,2%	1,9%	€/¥	130,82	-0,3%	-0,1%	ONCE OR (§)	1165	-0,7%	9,8%
VIX Index	23,4		7,1%					VSTOXX Index	30,1		1,4%

Economic Calendar

JP - Eco Watchers survey outlook Jan (49.5A 48.4E)

EUZ - sentix investor confidence Feb. (7.4 E)

DE - Industrial prod. (0.5% E m/m, -0.6% E y/y)

Dividends Calendar ex-date next day

Ex Div today

SODEXO (EXHO.PA)

2.2€ (2.4%)

Markets Recap (source Street account)

Asian markets are trading slightly weaker in very light trading on Monday. A number of regional indices are offline with China shut for the Lunar New Year holidays. Both the ASX and the Nikkei are off earlier lows. It has been a busy day on the Japanese macro calendar with the country reporting another current account surplus, a decline in real wages and a pickup in bank lending growth. The BoJ's summary of opinions also saw the potential for a negative impact from overseas developments. Miners are leading the ASX despite some softness in commo

dities on Friday. Data also showed a rebound in job advertisements, reinforcing the positive narrative around Aussie employment. Earlier, data revealed another large drop in China's FX reserves though the decline was smaller than consensus estimates.

US equities closed down today. Treasuries were weaker, with some curve flattening. The dollar was stronger, particularly on the euro and sterling crosses, after two days of declines. Gold was slightly higher. Oil was down, with WTI settling (2.6%).

The focus today was fixed on the January employment report, which showed below-consensus job growth and some upward movement in average hourly earnings. The dollar gained some strength in response, and there was continued debate about how the results may influence the trajectory of the

Fed's policy path. There were few other factors at play, and the market is now looking forward to the release of China's FX data this weekend and Fed Chair Yellen's Congressional testimony next week.

DATA and LNKD were hit by softer guidance, with both citing macro headwinds. Apparel names DECK and HBI disappointed. SYMC was a standout in a weak tech sector on news of a \$500M investment from Silver Lake. TSN had a high-quality beat and raise. Commercial strength was a focus for HIG.

Tech lagged the market with software and internet names selling off. Retail was weak for consumer discretionary. Energy trailed the tape. Biotech underperformed. Banks were relative outperformers for financials. Defensive sectors led the market.

Stocks Factor to watch today :

ZURICH INSURANCE: RBC expects ZURICH to cut dividend by 24% to 13CHF in 2016

ARCELORMITTAL : discussing sale of Steelton,

CASINO : has agreed to sell its stake in Big C for 3.1bn€ excluding debt.

AIR FRANCE : Passengers traffic rose 3.2% in January, while cargo traffic fell 6.4%

GLAXOSMITHKLINE: and VALNEVA signed a research and development collaboration.

Rating & TP Changes



VINCI : BUY vs. HOLD, FV 66€ vs. 64 @ *HSBC*

MUNICH RE : NEUTRAL vs. UNDERPERFORM @ *Credit Suisse*



VICAT : TP cut to 56€ vs. 64, NEUTRAL @ *BRYAN GARNIER*

ASTRAZENECA : HOLD vs. BUY @ *HSBC*

AB INBEV : TP cut to 133€ vs. 135, BUY @ *NOMURA*

CRH : TP cut to 24€ vs. 26, Neutral @ *Credit Suisse*

BUREAU VERITAS : TP cut to 8.96€ vs. 13.2, Neutral @ *CITI*

SAFRAN : TP cut to 55€ vs. 60 HOLD @ *Jefferies*

BNP PARIBAS : TP cut to 58 vs. 59 Equal Weight @ *Barclays*.

BNP PARIBAS : TP cut to 58 vs. 62 Outperform @ *RBC*

TECHNIP: TP cut to 25€ vs. 27 @ *Nomura*

ARCELORMITTAL : HOLD vs. BUY, TP 3.6€ vs. 5.5 @ *Berenberg*

LAFARGEHOLCIM : TP cut to 54CHF vs. 71, Underperform @ *Credit Suisse*

SAINT GOBAIN : TP cut to 32€ vs. 34 underperform @ *Credit Suisse*

HEIDELBERGCEMENT : TP cut to 57€ vs. 61, Underperform @ *Credit Suisse*

Technical Analysis

BURBERRY, CASINO, C. DIOR, SWATCH GROUP : at their highest YTD

ALLIANZ, GENERALI, FRESENIUS, ASTRAZENECA, ATOS, BAYER, HANNOVER RE, INFINEON, LUXOTTICA, MERCK KG : at their lowest YTD

⬇️Downward Signals⬇️

ARM, CRH, NOVOZYMES : 50D MAV crossing downward 200D MAV

FRESENIUS MED CARE : Stock price crossing downward 200d MAV.

Bryan Garnier ... Today's comment(s)

Vicat

RATING : NEUTRAL

Fair Value EUR56 vs. EUR64

We see some positive trends in the 2015 sales publication of Vicat: France is likely to gradually recover, US is still strong as well as Turkey. But competitions looks dense in West Africa, we are not that comfortable with visibility in India so far, while Kazakhstan currency devaluation will take its tolls in 2016. Besides, we struggle to estimate Egypt margin rebound trends. Finally, Switzerland looks currently subdued. For the 2015-2017 period, we downgrade our estimates by -3% in average for revenues and by -7% for the EBITDA. New FV at EUR56 vs EUR64. 14th of March FY results release might provide a better view on 2016 outlook. We are staying Neutral in time between. **NEUTRAL**.

Casino Guichard

RATING : BUY

Fair Value EUR54

Casino announced that it would sale its equity stake (i.e. 58.6%) in Big C for EUR3.1bn (excluding debt) to the TCC group vs EUR2.8bn currently in our SOTP (impact of EUR2.8 per share). The transaction multiple works out at 1.65x EV/Sales (high-end of expectations). Hence, the credit situation should dramatically improve, even beyond what was initially hoped by S&P. Hence, we do hope this good news will favorably influenced S&P as to its upcoming decision about a potential downgrade. **Positive**

Ingenico Group

RATING : BUY

Fair Value EUR150

Before a rich news flow (FY15 earnings results and first 2016 targets on 18th February, and then its strategic plan on 23rd March), we give our expectations and reiterate our investment case on the stock. The management's strategic plan should reassure the market and its initial guidances (both 2016e and 2019/20e) should be understood as worst-case scenarios (as usual). In the end, we expect the group to exceed its targets in view of its always-cautious financial communication, management's excellent track-record in terms of execution and the constant change in the group's profile towards more recurring and better quality sales (notably thanks to its development in Payment Services). =>

Positive

Innate Pharma

RATING : BUY

Fair Value EUR19 (+64%)

Innate Pharma announces the initiation of a Phase I evaluating monalizumab (anti-NKG2A) in combination with AZN's durvalumab (anti-PD-L1) in selected advanced solid tumors. Apart from the fact this should lead to an increase in consensus' estimates, we see this is as a first step in the collaboration with the big pharma as 1/ we expect other trials testing monalizumab with other AZN's compounds (like Lynparaza and Tagrisso); 2/ we think a tripartite collaboration involving AZN, IPH and Celgene is very likely. BUY reiterated with a FV of EUR19. **POSITIVE**
